Weight-Loss Stock Winners This Year Risk Being Losers in 2024
- Survey results suggest weight-loss fortunes could falter
- Novo Nordisk, Eli Lilly have been stock market winners in 2023
Novo Nordisk became Europe’s most-valuable listed company this year.
Photographer: Carsten Snejbjerg/BloombergThis article is for subscribers only.
Weight-loss drugmakers Novo Nordisk A/S and Eli Lilly & Co. are more likely to turn into laggards in 2024 than other stock market stars of this year. That’s according to Bloomberg’s latest Markets Live Pulse survey.
About 34% of respondents in the survey of 518 participants picked weight-loss drugmakers as this year’s winners that would most probably turn into losers next year. That compares with 31% who chose the so-called Magnificent Seven technology behemoths as potential underperformers, while the rest were split about evenly between Japanese and MSCI Latin American stocks.